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Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
Supplemental Materials
Mean ± SD 8.7 ± 13.5 8.4 ± 14.6 7.0 ± 11.3 6.9 ± 8.6
Median (range) 4.0 (1-47) 3.5 (1-101) 3.0 (1-83) 3.0 (1-33)
BMI body mass index; SD standard deviation a At study entry b Attack rate during enrollment. P = 0.510 comparing the normal, overweight, and obese categories. The underweight category was excluded from the comparison due to small sample size n.a. 0.174 0.011 < 0.001 Mean ± SD impact on duration of attack 0 to < 1 h 6 15.8 ± 16.7 154 10.6 ± 12.5 148 8.1 ± 11.0 71 5.9 ± 10.9 ≥ 1 h 6 18.7 ± 12.5 233 22.5 ± 22.5 201 14.8 ± 14.2 88 24.6 ± 21.4 P value n.a. < 0.001 < 0.001 < 0.001 0 to < 2 h 6 15.8 ± 16.7 226 12.4 ± 13.7 193 8.9 ± 12.1 92 7.4 ± 11.9 ≥ 2 h 6 18.7 ± 12.5 161 25.4 ± 24.6 156 15.8 ± 13.9 67 28.4 ± 22.1 P value n.a. < 0.001 < 0.001 < 0.001 BMI body mass index; n.a. not applicable because statistical comparison was not conducted due to small sample sizes; SD standard deviation .0 (0.3-120) BMI body mass index; SD standard deviation n = the number of patients a P values comparing average duration of attack at baseline between patients with normal/overweight/obese BMI: P = 0.429 at baseline, P = 0.530 at follow-up Note: average duration of untreated attacks corresponds to mean of average durations of untreated attacks at the skin, abdomen, larynx, and other sites.
Figure legends
Figure S1. Severity of icatibant-treated attacks by body mass index (BMI). P values comparing severity of attacks (very mild/mild/moderate vs severe/very severe): P = 0.146 for normal vs overweight; P = 0.972 for normal vs obese; P = 0.249 for overweight vs obese. n = number of attacks Figure S2 . Site of icatibant-treated attacks by body mass index (BMI). P values comparing frequency of attacks between patients with normal/overweight/obese BMI: P = 0.026 for skin attacks; P = 0.004 for abdominal attacks; P = 0.215 for laryngeal attacks; P = 0.142 for attacks affecting other organs. n = number of attacks Figure S3 . Outcomes of attacks treated with icatibant by body mass index (BMI). Analysis included attacks with data for all three outcomes. Boxes depict 25th percentile, median, and 75th percentile. Mean indicated with "○". P values refer to comparisons versus normal BMI: time to treatment, P = 0.016 versus overweight and P = 0.496 versus obese; duration of attack, P < 0.001 versus overweight and P = 0.417 versus obese; time to resolution, P < 0.001 versus overweight and P = 0.178 versus obese. Max = maximum value. n = number of attacks Figure S1 .
